A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published today in the journal Lancet Infectious Disease. If the vaccine is ultimately found to be safe and effective, it could offer crucial protection for contacts (family members, neighbors, etc.) of patients with confirmed Ebola disease in future epidemics, thereby helping to interrupt transmission. Larger trials of the vaccine sponsored, by GSK Biologicals, have already begun.
The study, carried out in Mali, West Africa and Baltimore, included the first testing of this vaccine in adult health care workers and other at-risk persons in Africa. It identified the dose to be used in subsequent clinical trials and for large-scale manufacture of the vaccine. The researchers say that if larger trials (some already ongoing at CVD-Mali) corroborate the vaccine’s clinical acceptability and immunogenicity, and with evidence of protection from future field trials or from non-human primate challenge models, the vaccine could obtain regulatory approvals to become a tool to interrupt transmission in future outbreaks. This would be achieved by vaccinating all people who have come into contact with confirmed Ebola cases.
The investigators also found that the administration of a booster vaccination with another vector vaccine producing Ebola virus antigens led to further enhanced immune responses likely to be associated with long-lived protection. This “prime-boost” approach provides a way to vaccinate health care workers and other front-line workers who live in areas where Ebola poses a threat to re-emerge and who need prior enduring protection.
The trial was carried out by a group of faculty researchers within the Center for Vaccine Development (CVD) of the University of Maryland School of Medicine (UM SOM), led by Milagritos D. Tapia, MD and Kirsten Lyke, MD, collaborating closely with Professor Samba O. Sow, MD, MSc, Director General of the Center for Vaccine Development of Mali (CVD-Mali, an institution jointly maintained by the Ministry of Health of Mali and CVD-UM SOM).
Drs. Tapia and Lyke are also Associate Professors in the Department of Pediatrics and Medicine, respectively, at CVD-UM SOM., provided overall coordination of this study that evaluated the experimental Ebola vaccine (ChAd3-EBO-Z) developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and GlaxoSmithKline (GSK). Other key partners in the study included the University of Oxford’s Jenner Institute and the World Health Organization.
The study was the result of a consortium of the World Health Organization (WHO), the VRC, the Jenner Institute at the University of Oxford, CVD-Mali, CVD-UM SOM, and GSK Biologicals (manufacturer of the vaccine).
The study also involved others at CVD-UM SOM, including Marcelo B. Sztein, MD, and, James D. Campbell, MD, MS, both of whom are Professors of Pediatrics at UM SOM, as well as Rezwanul Wahid, PhD, Assistant Professor of Pediatrics at UM SOM.
“This is a crucial step on the road to using this vaccine in humans,” said Dr. Levine. “This gives us essential information that the vaccine is not only well-tolerated but the high dose stimulates strong immune responses in adults in West Africa, the global region where the Ebola outbreak was rampant last year.”
The Latest on: Ebola vaccine
[google_news title=”” keyword=”Ebola vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Ebola vaccine
- Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africaon April 26, 2024 at 10:30 pm
Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa: Princeton, New Jersey Saturday, April 27, 2024, 11:00 Hrs [IST] Soligenix, Inc, a ...
- Ebola Outbreak in West Africa, 2013-2014on April 24, 2024 at 5:00 pm
The Ebola virus disease outbreak now ravaging parts of West Africa is the largest on record. In fact, West Africa has seen more cases of the disease in 2014 than have been seen in all other ...
- Bavarian Nordic gets grant for vaccine for protective immunity against filovirus infectionon April 24, 2024 at 6:13 am
Discover the groundbreaking patent by Bavarian Nordic AS for a vaccine combo that fights Ebola & Marburg viruses. Learn about the specific adenovirus & MVA vectors for protective immunity.
- Ebola's exponential growthon April 23, 2024 at 5:00 pm
Until and unless a vaccine becomes available in very large quantities, the only way to stop the exponential spread of Ebola in the affected countries is to isolate the victims, a task that is very ...
- This Kenya Cave, Believed To Be Source Of Ebola, Could Cause Next Pandemic: WHO Issues Warning About Marburg Virus Outbreakon April 22, 2024 at 10:29 pm
The world's deadliest cave Kitum, located in Mount Elgon National Park in Kenya, could cause the next pandemic. Read on to know more.
- Believed to be the source of Ebola, this Kenya cave could be ground zero for the next pandemicon April 22, 2024 at 6:54 pm
Located in Kenya's Mount Elgon National Park, the Kitum Cave was reportedly the origin point for the Ebola and Marburg viruses, of which the latter has been termed as 'epidemic-prone' by the World ...
- This Kenya Cave, Believed To Be Source Of Ebola, Could Cause Next Pandemicon April 22, 2024 at 9:11 am
The 600-foot-deep cave has been continuously dug and expanded by elephants, only to have disease-carrying bats make it their home.
- New study rates influenza as the top pandemic threat, here’s whyon April 21, 2024 at 6:50 am
Other highly ranked pathogens included "Disease X", and the viruses responsible for SARS, SARS-CoV-2, and Ebola.
- Soligenix bags orpan drug designation for Marburg virus vaccineon April 15, 2024 at 11:49 am
The US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax, Soligenix’s vaccine for the prevention and post-exposure prophylaxis against Marburg ...
- Soligenix Granted Orphan Drug Designation for Vaccine to Treat MARV Infectionon April 15, 2024 at 10:12 am
Soligenix, Inc. announced that the Office of Orphan Products Development of the FDA has granted orphan drug status ...
via Bing News